


**Amendments to the Claims**

The following listing of claims replaces all prior versions of listing of claims in the application:

1. (Currently Amended) A pharmaceutical composition, comprising: a compound of formula (1) in solid form:



(1)

together with a pharmaceutically acceptable carrier or excipient,


provided that the compound of formula (1) is present in polymorphic Form A ~~and is substantially free of other polymorphic forms.~~

2. (Currently Amended) The pharmaceutical composition of claim 1 in which the compound of formula (1) is present as orthorhombic crystals.
3. (Currently Amended) The pharmaceutical composition of claim 1, which is formulated as ~~in the form of~~ a tablet or capsule.
4. (Cancelled)
5. (Currently Amended) The pharmaceutical composition of claim 1, wherein ~~at least about 90% of~~ the compound of formula (1) exhibits no PXRD peaks of polymorphic forms B and C at about is polymorphic Form A, as defined by PXRD peak heights around 9° 2-theta.
6. (Currently Amended) The pharmaceutical composition of claim 1, further comprising

lactose and microcrystalline cellulose.

7. (Original ) The tablet of claim 3, which weighs between 250 and 500 mg.

8. (Currently Amended) A solid composition comprising isolated crystals of the compound of formula (1)



(1)

in which said crystals ~~the isolated crystals of compound (1)~~ are present in polymorphic Form A ~~and substantially free of other polymorphs~~.

9. (Original) The composition of claim 8, wherein ~~the isolated~~ said crystals of compound (1) are present as orthorhombic crystals.

10. (Cancelled)

11. (Currently Amended) The composition of claim 8, wherein ~~the isolated~~ said crystals exhibit no PXRD peaks of polymorphic forms B and C at about ~~are at least about 90%~~ polymorphic Form A, as defined by PXRD peak heights around 9° 2-theta.

12. (Cancelled)